Activin A: an emerging target for improving cancer treatment?

References

• Gregory SJ, Kaiser UB. Regulation of gonadotropins by inhibin and activin. Semin Reprod Med. 2004;22:253–267.
   PubMed Web of Science ®Google Scholar
• Namwanje M, Brown CW. Activins and inhibins: roles in development, physiology, and disease. Cold Spring Harb Perspect Biol. 2016;8. DOI:10.1101/cshperspect.a021881
   PubMed Web of Science ®Google Scholar
• Lewis KA, Gray PC, Blount AL, et al. Betaglycan binds inhibin and can mediate functional antagonism of activin signalling. Nature. 2000;404:411–414..
   PubMed Web of Science ®Google Scholar
• Wang X, Fischer G, Hyvonen M. Structure and activation of pro-activin A. Nat Commun. 2016;7:12052.
   PubMed Web of Science ®Google Scholar
• Weiss A, Attisano L. The TGFbeta superfamily signaling pathway. Wiley Interdiscip Rev Dev Biol. 2013;2:47–63.
   PubMed Web of Science ®Google Scholar
• Michael IP, Saghafinia S, Tichet M, et al. ALK7 signaling manifests a homeostatic tissue barrier that is abrogated during tumorigenesis and metastasis. Dev Cell. 2019;49:409–24 e6.
   PubMed Web of Science ®Google Scholar
• Tsuchida K, Nakatani M, Yamakawa N, et al. Activin isoforms signal through type I receptor serine/threonine kinase ALK7. Mol Cell Endocrinol. 2004;220:59–65.
   PubMed Web of Science ®Google Scholar
• Bertolino P, Holmberg R, Reissmann E, et al. Activin B receptor ALK7 is a negative regulator of pancreatic beta-cell function. Proc Natl Acad Sci U S A. 2008;105:7246–7251.
   PubMed Web of Science ®Google Scholar
• Pituello F, Yamada G, Gruss P. Activin A inhibits Pax-6 expression and perturbs cell differentiation in the developing spinal cord in vitro. Proc Natl Acad Sci U S A. 1995;92:6952–6956.
   PubMed Web of Science ®Google Scholar
• Attardi B, Miklos J. Rapid stimulatory effect of activin-A on messenger RNA encoding the follicle-stimulating hormone beta-subunit in rat pituitary cell cultures. Mol Endocrinol. 1990;4:721–726.
   PubMedGoogle Scholar
• Kaneda H, Arao T, Matsumoto K, et al. Activin A inhibits vascular endothelial cell growth and suppresses tumour angiogenesis in gastric cancer. Br J Cancer. 2011;105:1210–1217.
   PubMed Web of Science ®Google Scholar
• Burdette JE, Jeruss JS, Kurley SJ, et al. Activin A mediates growth inhibition and cell cycle arrest through Smads in human breast cancer cells. Cancer Res. 2005;65:7968–7975.
   PubMed Web of Science ®Google Scholar
• Bartholin L, Maguer-Satta V, Hayette S, et al. Transcription activation of FLRG and follistatin by activin A, through Smad proteins, participates in a negative feedback loop to modulate activin A function. Oncogene. 2002;21:2227–2235.
   PubMed Web of Science ®Google Scholar
• Ishisaki A, Yamato K, Nakao A, et al. Smad7 is an activin-inducible inhibitor of activin-induced growth arrest and apoptosis in mouse B cells. J Biol Chem. 1998;273:24293–24296.
   PubMed Web of Science ®Google Scholar
• Schmierer B, Hill CS. TGFbeta-SMAD signal transduction: molecular specificity and functional flexibility. Nat Rev Mol Cell Biol. 2007;8:970–982..
   PubMed Web of Science ®Google Scholar
• Hata A, Chen YG. TGF-beta signaling from receptors to smads. Cold Spring Harb Perspect Biol. 2016;8. DOI:10.1101/cshperspect.a022061
   PubMed Web of Science ®Google Scholar
• Miller DSJ, Schmierer B, Hill CS. TGF-β family ligands exhibit distinct signalling dynamics that are driven by receptor localisation. J Cell Sci. 2018;6(14):jcs234039.
   Google Scholar
• de Guise C, Lacerte A, Rafiei S, et al. Activin inhibits the human Pit-1 gene promoter through the p38 kinase pathway in a Smad-independent manner. Endocrinology. 2006;147:4351–4362.
   PubMed Web of Science ®Google Scholar
• Dean M, Davis DA, Burdette JE. Activin A stimulates migration of the fallopian tube epithelium, an origin of high-grade serous ovarian cancer, through non-canonical signaling. Cancer Lett. 2017;391:114–124.
   PubMed Web of Science ®Google Scholar
• Tamminen JA, Yin M, Ronty M, et al. Overexpression of activin-A and -B in malignant mesothelioma - attenuated Smad3 signaling responses and ERK activation promote cell migration and invasive growth. Exp Cell Res. 2015;332:102–115.
   PubMed Web of Science ®Google Scholar
• Shao L, Frigon NL Jr., Sehy DW, et al. Regulation of production of activin A in human marrow stromal cells and monocytes. Exp Hematol. 1992;20:1235–1242.
   PubMed Web of Science ®Google Scholar
• Shao LE, Frigon NL Jr., Yu A, et al. Contrasting effects of inflammatory cytokines and glucocorticoids on the production of activin A in human marrow stromal cells and their implications. Cytokine. 1998;10:227–235.
   PubMed Web of Science ®Google Scholar
• Breit S, Ashman K, Wilting J, et al. The N-myc oncogene in human neuroblastoma cells: down-regulation of an angiogenesis inhibitor identified as activin A. Cancer Res. 2000;60:4596–4601.
   PubMed Web of Science ®Google Scholar
• Makanji Y, Zhu J, Mishra R, et al. Inhibin at 90: from discovery to clinical application, a historical review. Endocr Rev. 2014;35:747–794.
   PubMed Web of Science ®Google Scholar
• Mellor SL, Ball EM, O’Connor AE, et al. Activin betaC-subunit heterodimers provide a new mechanism of regulating activin levels in the prostate. Endocrinology. 2003;144:4410–4419.
   PubMed Web of Science ®Google Scholar
• Nakamura T, Takio K, Eto Y, et al. Activin-binding protein from rat ovary is follistatin. Science. 1990;247:836–838..
   PubMed Web of Science ®Google Scholar
• Sugino K, Kurosawa N, Nakamura T, et al. Molecular heterogeneity of follistatin, an activin-binding protein. Higher affinity of the carboxyl-terminal truncated forms for heparan sulfate proteoglycans on the ovarian granulosa cell. J Biol Chem. 1993;268:15579–15587.
   PubMed Web of Science ®Google Scholar
• Glister C, Regan SL, Samir M, et al. Gremlin, Noggin, Chordin and follistatin differentially modulate BMP induced suppression of androgen secretion by bovine ovarian theca cells. J Mol Endocrinol. 2019;62:15–25.
   Web of Science ®Google Scholar
• Amthor H, Nicholas G, McKinnell I, et al. Follistatin complexes Myostatin and antagonises Myostatin-mediated inhibition of myogenesis. Dev Biol. 2004;270:19–30.
   PubMed Web of Science ®Google Scholar
• Tsuchida K, Arai KY, Kuramoto Y, et al. Identification and characterization of a novel follistatin-like protein as a binding protein for the TGF-beta family. J Biol Chem. 2000;275:40788–40796.
   PubMed Web of Science ®Google Scholar
• Martello G, Zacchigna L, Inui M, et al. MicroRNA control of Nodal signalling. Nature. 2007;449:183–188..
   PubMed Web of Science ®Google Scholar
• Li D, Duan M, Feng Y, et al. MiR-146a modulates macrophage polarization in systemic juvenile idiopathic arthritis by targeting INHBA. Mol Immunol. 2016;77:205–212.
   PubMed Web of Science ®Google Scholar
• Seder CW, Hartojo W, Lin L, et al. Upregulated INHBA expression may promote cell proliferation and is associated with poor survival in lung adenocarcinoma. Neoplasia. 2009;11:388–396.
   PubMed Web of Science ®Google Scholar
• Seder CW, Hartojo W, Lin L, et al. INHBA overexpression promotes cell proliferation and may be epigenetically regulated in esophageal adenocarcinoma. J Thorac Oncol. 2009;4:455–462.
   PubMed Web of Science ®Google Scholar
• Hoda MA, Munzker J, Ghanim B, et al. Suppression of activin A signals inhibits growth of malignant pleural mesothelioma cells. Br J Cancer. 2012;107:1978–1986.
   PubMed Web of Science ®Google Scholar
• Razanajaona D, Joguet S, Ay A-S, et al. Silencing of FLRG, an antagonist of activin, inhibits human breast tumor cell growth. Cancer Res. 2007;67(15):7223–7229.
   PubMed Web of Science ®Google Scholar
• Grusch M, Drucker C, Peter-Vorosmarty B, et al. Deregulation of the activin/follistatin system in hepatocarcinogenesis. J Hepatol. 2006;45:673–680.
   PubMed Web of Science ®Google Scholar
• Jung B, Doctolero RT, Tajima A, et al. Loss of activin receptor type 2 protein expression in microsatellite unstable colon cancers. Gastroenterology. 2004;126:654–659.
   PubMedGoogle Scholar
• Jakowlew SB. Transforming growth factor-beta in cancer and metastasis. Cancer Metastasis Rev. 2006;25:435–457.
   PubMed Web of Science ®Google Scholar
• Schwall RH, Robbins K, Jardieu P, et al. Activin induces cell death in hepatocytes in vivo and in vitro. Hepatology. 1993;18:347–356..
   PubMed Web of Science ®Google Scholar
• Zauberman A, Oren M, Zipori D. Involvement of p21(WAF1/Cip1), CDK4 and Rb in activin A mediated signaling leading to hepatoma cell growth inhibition. Oncogene. 1997;15:1705–1711.
   PubMed Web of Science ®Google Scholar
• Vejda S, Erlach N, Peter B, et al. Expression of activins C and E induces apoptosis in human and rat hepatoma cells. Carcinogenesis. 2003;24:1801–1809.
   PubMed Web of Science ®Google Scholar
• Dalkin AC, Gilrain JT, Bradshaw D, et al. Activin inhibition of prostate cancer cell growth: selective actions on androgen-responsive LNCaP cells. Endocrinology. 1996;137:5230–5235.
   PubMed Web of Science ®Google Scholar
• Jung BH, Beck SE, Cabral J, et al. Activin type 2 receptor restoration in MSI-H colon cancer suppresses growth and enhances migration with activin. Gastroenterology. 2007;132:633–644.
   PubMed Web of Science ®Google Scholar
• Jiang L, Si T, Yu M, et al. The tumor suppressive role of inhibin betaA in diffuse large B-cell lymphoma. Leuk Lymphoma. 2018;59:1202–1212.
   PubMed Web of Science ®Google Scholar
• Panopoulou E, Murphy C, Rasmussen H, et al. Activin A suppresses neuroblastoma xenograft tumor growth via antimitotic and antiangiogenic mechanisms. Cancer Res. 2005;65:1877–1886.
   PubMed Web of Science ®Google Scholar
• Ohga E, Matsuse T, Teramoto S, et al. Effects of activin A on proliferation and differentiation of human lung fibroblasts. Biochem Biophys Res Commun. 1996;228:391–396.
   PubMed Web of Science ®Google Scholar
• Gotzmann J, Mikula M, Eger A, et al. Molecular aspects of epithelial cell plasticity: implications for local tumor invasion and metastasis. Mutat Res. 2004;566:9–20.
   PubMed Web of Science ®Google Scholar
• Dignass AU, Jung S, Harder-d’Heureuse J, et al. Functional relevance of activin A in the intestinal epithelium. Scand J Gastroenterol. 2002;37:936–943.
   PubMed Web of Science ®Google Scholar
• Nomura M, Tanaka K, Wang L, et al. Activin type IB receptor signaling in prostate cancer cells promotes lymph node metastasis in a xenograft model. Biochem Biophys Res Commun. 2013;430:340–346.
   PubMed Web of Science ®Google Scholar
• Kalli M, Mpekris F, Wong CK, et al. Activin A signaling regulates IL13Ralpha2 expression to promote breast cancer metastasis. Front Oncol. 2019;9:32.
   PubMed Web of Science ®Google Scholar
• Chang KP, Kao HK, Liang Y, et al. Overexpression of activin A in oral squamous cell carcinoma: association with poor prognosis and tumor progression. Ann Surg Oncol. 2010;17:1945–1956.
   PubMed Web of Science ®Google Scholar
• Yi Y, Cheng J-C, Klausen C, et al. Activin A promotes ovarian cancer cell migration by suppressing E-cadherin expression. Exp Cell Res. 2019;382(2):111471.
   PubMed Web of Science ®Google Scholar
• Bashir M, Damineni S, Mukherjee G, et al. Activin-A signaling promotes epithelial–mesenchymal transition, invasion, and metastatic growth of breast cancer. NPJ Breast Cancer. 2015;1(1):15007.
   PubMedGoogle Scholar
• Loomans HA, Andl CD. Intertwining of Activin A and TGFbeta Signaling: dual Roles in Cancer Progression and Cancer Cell Invasion. Cancers (Basel). 2014;7:70–91.
   PubMed Web of Science ®Google Scholar
• Hyuga S, Kawasaki N, Hashimoto O, et al. Possible role of hepatocyte growth factor/scatter factor and activin A produced by the target organ in liver metastasis. Cancer Lett. 2000;153(1–2):137–143.
   PubMed Web of Science ®Google Scholar
• Portale F, Cricri G, Bresolin S, et al. ActivinA: a new leukemia-promoting factor conferring migratory advantage to B-cell precursor-acute lymphoblastic leukemic cells. Haematologica. 2019;104:533–545.
   PubMed Web of Science ®Google Scholar
• Ferrara N, Hillan KJ, Gerber HP, et al. Discovery and development of bevacizumab, an anti-VEGF antibody for treating cancer. Nat Rev Drug Discov. 2004;3:391–400.
   PubMed Web of Science ®Google Scholar
• Kozian DH, Ziche M, Augustin HG. The activin-binding protein follistatin regulates autocrine endothelial cell activity and induces angiogenesis. Lab Invest. 1997;76:267–276.
   PubMed Web of Science ®Google Scholar
• Maeshima K, Maeshima A, Hayashi Y, et al. Crucial role of activin a in tubulogenesis of endothelial cells induced by vascular endothelial growth factor. Endocrinology. 2004;145:3739–3745.
   PubMed Web of Science ®Google Scholar
• Krneta J, Kroll J, Alves F, et al. Dissociation of angiogenesis and tumorigenesis in follistatin- and activin-expressing tumors. Cancer Res. 2006;66:5686–5695..
   PubMed Web of Science ®Google Scholar
• Heinz M, Niederleithner HL, Puujalka E, et al. Activin A is anti-lymphangiogenic in a melanoma mouse model. J Invest Dermatol. 2015;135:212–221.
   PubMed Web of Science ®Google Scholar
• Phillips DJ, de Kretser DM, Hedger MP. Activin and related proteins in inflammation: not just interested bystanders. Cytokine Growth Factor Rev. 2009;20:153–164.
   PubMed Web of Science ®Google Scholar
• Morianos I, Papadopoulou G, Semitekolou M, et al. Activin-A in the regulation of immunity in health and disease. J Autoimmun. 2019;104:102314.
   PubMed Web of Science ®Google Scholar
• Antsiferova M, Huber M, Meyer M, et al. Activin enhances skin tumourigenesis and malignant progression by inducing a pro-tumourigenic immune cell response. Nat Commun. 2011;2:576..
   PubMed Web of Science ®Google Scholar
• Antsiferova M, Piwko-Czuchra A, Cangkrama M, et al. Activin promotes skin carcinogenesis by attraction and reprogramming of macrophages. EMBO Mol Med. 2017;9:27–45.
   PubMed Web of Science ®Google Scholar
• Donovan P, Dubey OA, Kallioinen S, et al. Paracrine Activin-A signaling promotes melanoma growth and metastasis through immune evasion. J Invest Dermatol. 2017;137:2578–2587.
   PubMed Web of Science ®Google Scholar
• Ni X, Tao J, Barbi J, et al. YAP is essential for treg-mediated suppression of antitumor immunity. Cancer Discov. 2018;8:1026–1043.
   PubMed Web of Science ®Google Scholar
• Sainz B Jr., Alcala S, Garcia E, et al. Microenvironmental hCAP-18/LL-37 promotes pancreatic ductal adenocarcinoma by activating its cancer stem cell compartment. Gut. 2015;64:1921–1935.
   PubMed Web of Science ®Google Scholar
• Xiao L, Yuan X, Sharkis SJ. Activin A maintains self-renewal and regulates fibroblast growth factor, Wnt, and bone morphogenic protein pathways in human embryonic stem cells. Stem Cells. 2006;24:1476–1486..
   PubMed Web of Science ®Google Scholar
• Jiang J, Au M, Lu K, et al. Generation of insulin-producing islet-like clusters from human embryonic stem cells. Stem Cells. 2007;25:1940–1953.
   PubMed Web of Science ®Google Scholar
• Cai J, Zhao Y, Liu Y, et al. Directed differentiation of human embryonic stem cells into functional hepatic cells. Hepatology. 2007;45:1229–1239.
   PubMed Web of Science ®Google Scholar
• Lonardo E, Hermann PC, Mueller MT, et al. Nodal/Activin signaling drives self-renewal and tumorigenicity of pancreatic cancer stem cells and provides a target for combined drug therapy. Cell Stem Cell. 2011;9:433–446.
   PubMed Web of Science ®Google Scholar
• Liu R, Wang JH, Xu C, et al. Activin pathway enhances colorectal cancer stem cell self-renew and tumor progression. Biochem Biophys Res Commun. 2016;479:715–720.
   PubMed Web of Science ®Google Scholar
• Wamsley JJ, Kumar M, Allison DF, et al. Activin Upregulation by NF-κB Is Required to Maintain Mesenchymal Features of Cancer Stem–like Cells in Non–Small Cell Lung Cancer. Cancer Res. 2015;75(2):426–435.
   PubMed Web of Science ®Google Scholar
• Rodrigues CFD, Serrano E, Patricio MI, et al. Stroma-derived IL-6, G-CSF and Activin-A mediated dedifferentiation of lung carcinoma cells into cancer stem cells. Sci Rep. 2018;8:11573.
   PubMed Web of Science ®Google Scholar
• Ohno Y, Shingyoku S, Miyake S, et al. Differential regulation of the sphere formation and maintenance of cancer-initiating cells of malignant mesothelioma via CD44 and ALK4 signaling pathways. Oncogene. 2018;37:6357–6367.
   PubMed Web of Science ®Google Scholar
• Cioffi M, Trabulo SM, Sanchez-Ripoll Y, et al. The miR-17-92 cluster counteracts quiescence and chemoresistance in a distinct subpopulation of pancreatic cancer stem cells. Gut. 2015;64:1936–1948.
   PubMed Web of Science ®Google Scholar
• Marini KD, Croucher DR, McCloy RA, et al. Inhibition of activin signaling in lung adenocarcinoma increases the therapeutic index of platinum chemotherapy. Sci Transl Med2018;10. DOI:10.1126/scitranslmed.aat3504.
   PubMed Web of Science ®Google Scholar
• Paajanen J, Ilonen I, Lauri H, et al. Elevated circulating Activin A levels in patients with malignant pleural mesothelioma are related to cancer cachexia and reduced response to platinum-based chemotherapy. Clin Lung Cancer. 2020;21:e142–e150.
   Web of Science ®Google Scholar
• Tanaka T, Toujima S, Umesaki N. Growth-inhibitory signals by activin A do not affect anticancer drug-sensitivity and acquired multi-drug-resistance in human ovarian endometrioid adenocarcinoma OVK-18 cells. Oncol Rep. 2004;11:667–671.
   PubMed Web of Science ®Google Scholar
• Huang YW, Lee WH, Tsai YH, et al. Activin A induction of erythroid differentiation sensitizes K562 chronic myeloid leukemia cells to a subtoxic concentration of imatinib. Am J Physiol Cell Physiol. 2014;306:C37–44.
   PubMed Web of Science ®Google Scholar
• Matzuk MM, Finegold MJ, Mather JP, et al. Development of cancer cachexia-like syndrome and adrenal tumors in inhibin-deficient mice. Proc Natl Acad Sci U S A. 1994;91:8817–8821.
   PubMed Web of Science ®Google Scholar
• Coerver KA, Woodruff TK, Finegold MJ, et al. Activin signaling through activin receptor type II causes the cachexia-like symptoms in inhibin-deficient mice. Mol Endocrinol. 1996;10:534–543.
   PubMed Web of Science ®Google Scholar
• Zhou X, Wang JL, Lu J, et al. Reversal of cancer cachexia and muscle wasting by ActRIIB antagonism leads to prolonged survival. Cell. 2010;142:531–543..
   PubMed Web of Science ®Google Scholar
• Togashi Y, Kogita A, Sakamoto H, et al. Activin signal promotes cancer progression and is involved in cachexia in a subset of pancreatic cancer. Cancer Lett. 2015;356:819–827.
   PubMed Web of Science ®Google Scholar
• Chen JL, Walton KL, Winbanks CE, et al. Elevated expression of activins promotes muscle wasting and cachexia. Faseb J. 2014;28:1711–1723.
   PubMed Web of Science ®Google Scholar
• Winbanks CE, Murphy KT, Bernardo BC, et al. Smad7 gene delivery prevents muscle wasting associated with cancer cachexia in mice. Sci Transl Med. 2016;8:348ra98.
   PubMed Web of Science ®Google Scholar
• Loumaye A, de Barsy M, Nachit M, et al. Role of Activin A and myostatin in human cancer cachexia. J Clin Endocrinol Metab. 2015;100:2030–2038.
   PubMed Web of Science ®Google Scholar
• Hatakeyama S, Summermatter S, Jourdain M, et al. ActRII blockade protects mice from cancer cachexia and prolongs survival in the presence of anti-cancer treatments. Skelet Muscle. 2016;6:26.
   PubMed Web of Science ®Google Scholar
• Barreto R, Kitase Y, Matsumoto T, et al. ACVR2B/Fc counteracts chemotherapy-induced loss of muscle and bone mass. Sci Rep. 2017;7:14470.
   PubMed Web of Science ®Google Scholar
• Vallet S, Mukherjee S, Vaghela N, et al. Activin A promotes multiple myeloma-induced osteolysis and is a promising target for myeloma bone disease. Proc Natl Acad Sci U S A. 2010;107:5124–5129.
   PubMed Web of Science ®Google Scholar
• Carrancio S, Markovics J, Wong P, et al. An activin receptor IIA ligand trap promotes erythropoiesis resulting in a rapid induction of red blood cells and haemoglobin. Br J Haematol. 2014;165:870–882.
   PubMed Web of Science ®Google Scholar
• Raftopoulos H, Laadem A, Hesketh PJ, et al. Sotatercept (ACE-011) for the treatment of chemotherapy-induced anemia in patients with metastatic breast cancer or advanced or metastatic solid tumors treated with platinum-based chemotherapeutic regimens: results from two phase 2 studies. Support Care Cancer. 2016;24:1517–1525.
   PubMed Web of Science ®Google Scholar
• Fields SZ, Parshad S, Anne M, et al. Activin receptor antagonists for cancer-related anemia and bone disease. Expert Opin Investig Drugs. 2013;22:87–101.
   PubMed Web of Science ®Google Scholar
• Pirisi M, Fabris C, Luisi S, et al. Evaluation of circulating activin-A as a serum marker of hepatocellular carcinoma. Cancer Detect Prev. 2000;24:150–155.
   PubMedGoogle Scholar
• Reis FM, Cobellis L, Tameirao LC, et al. Serum and tissue expression of activin a in postmenopausal women with breast cancer. J Clin Endocrinol Metab. 2002;87(5):2277–2282.
   PubMed Web of Science ®Google Scholar
• Hoda MA, Rozsas A, Lang E, et al. High circulating activin A level is associated with tumor progression and predicts poor prognosis in lung adenocarcinoma. Oncotarget. 2016;7:13388–13399.
   PubMedGoogle Scholar
• Hoda MA, Dong Y, Rozsas A, et al. Circulating activin A is a novel prognostic biomarker in malignant pleural mesothelioma - A multi-institutional study. Eur J Cancer. 2016;63:64–73.
   PubMed Web of Science ®Google Scholar
• Kim SH, Kim JW, Hwang IG, et al. Serum biomarkers for predicting overall survival and early mortality in older patients with metastatic solid tumors. J Geriatr Oncol. 2019;10:749–756.
   PubMed Web of Science ®Google Scholar
• Leto G, Incorvaia L, Badalamenti G, et al. Activin A circulating levels in patients with bone metastasis from breast or prostate cancer. Clin Exp Metastasis. 2006;23:117–122.
   PubMed Web of Science ®Google Scholar
• Loumaye A, de Barsy M, Nachit M, et al. Circulating Activin A predicts survival in cancer patients. J Cachexia Sarcopenia Muscle. 2017;8:768–777.
   PubMed Web of Science ®Google Scholar
• Schuster C, Akslen LA, Stokowy T, et al. Predictive value of angiogenic proteins in patients with metastatic melanoma treated with bevacizumab monotherapy. J Pathol Clin Res. 2019;5:53–62.
   PubMedGoogle Scholar
• Okano M, Yamamoto H, Ohkuma H, et al. Significance of INHBA expression in human colorectal cancer. Oncol Rep. 2013;30:2903–2908.
   PubMed Web of Science ®Google Scholar
• Oshima T, Yoshihara K, Aoyama T, et al. Relation of INHBA gene expression to outcomes in gastric cancer after curative surgery. Anticancer Res. 2014;34:2303–2309.
   PubMed Web of Science ®Google Scholar
• Kelner N, Rodrigues PC, Bufalino A, et al. Activin A immunoexpression as predictor of occult lymph node metastasis and overall survival in oral tongue squamous cell carcinoma. Head Neck. 2015;37(4):479–486.
   PubMed Web of Science ®Google Scholar
• Mylonas I. Inhibin-betaA subunit immunolabeling as a prognostic factor in endometrioid adenocarcinomas: a matter of evaluation? Arch Gynecol Obstet. 2011;284:467–476.
   PubMed Web of Science ®Google Scholar
• Lee HY, Li CC, Huang CN, et al. INHBA overexpression indicates poor prognosis in urothelial carcinoma of urinary bladder and upper tract. J Surg Oncol. 2015;111:414–422.
   PubMed Web of Science ®Google Scholar
• Si T, Lu Y, Li F, et al. High expression of INHBA is an adverse prognostic factor for de novo acute myeloid leukemia. Leuk Lymphoma. 2018;59:114–120.
   PubMed Web of Science ®Google Scholar
• Vanhoutte F, Liang S, Ruddy M, et al. Pharmacokinetics and pharmacodynamics of garetosmab (Anti-Activin A): results from a first-in-human Phase 1 study. J Clin Pharmacol. 2020 Jun 18. online ahead of print. DOI:10.1002/jcph.1638
   PubMedGoogle Scholar
• Lach-Trifilieff E, Minetti GC, Sheppard K, et al. An antibody blocking activin type II receptors induces strong skeletal muscle hypertrophy and protects from atrophy. Mol Cell Biol. 2014;34:606–618.
   PubMed Web of Science ®Google Scholar
• Rooks D, Praestgaard J, Hariry S, et al. Treatment of sarcopenia with Bimagrumab: results from a Phase II, randomized, controlled, proof-of-concept study. J Am Geriatr Soc. 2017;65:1988–1995.
   PubMed Web of Science ®Google Scholar
• Polkey MI, Praestgaard J, Berwick A, et al. Activin Type II receptor blockade for treatment of muscle depletion in chronic obstructive pulmonary disease. a randomized trial. Am J Respir Crit Care Med. 2019;199:313–320.
   PubMed Web of Science ®Google Scholar
• Hanna MG, Badrising UA, Benveniste O, et al. Safety and efficacy of intravenous bimagrumab in inclusion body myositis (RESILIENT): a randomised, double-blind, placebo-controlled phase 2b trial. Lancet Neurol. 2019;18:834–844.
   PubMed Web of Science ®Google Scholar
• Motta I, Scaramellini N, Cappellini MD. Investigational drugs in phase I and phase II clinical trials for thalassemia. Expert Opin Investig Drugs. 2017;26:793–802.
   PubMed Web of Science ®Google Scholar
• Verma A, Suragani RNVS, Aluri S, et al. Biological basis for efficacy of activin receptor ligand traps in myelodysplastic syndromes. J Clin Invest. 2020;130(2):582–589.
   PubMed Web of Science ®Google Scholar
• Abdulkadyrov KM, Salogub GN, Khuazheva NK, et al. Sotatercept in patients with osteolytic lesions of multiple myeloma. Br J Haematol. 2014;165:814–823.
   PubMed Web of Science ®Google Scholar
• Tao JJ, Cangemi NA, Makker V, et al. First-in-Human Phase I study of the Activin A inhibitor, STM 434, in patients with granulosa cell ovarian cancer and other advanced solid tumors. Clin Cancer Res. 2019;25:5458–5465.
   PubMed Web of Science ®Google Scholar
• Welt CK, Lambert-Messerlian G, Zheng W, et al. Presence of activin, inhibin, and follistatin in epithelial ovarian carcinoma. J Clin Endocrinol Metab. 1997;82:3720–3727.
   PubMed Web of Science ®Google Scholar
• Pearsall RS, Davies MV, Cannell M, et al. Follistatin-based ligand trap ACE-083 induces localized hypertrophy of skeletal muscle with functional improvement in models of neuromuscular disease. Sci Rep. 2019;9:11392.
   PubMed Web of Science ®Google Scholar
• Mendell JR, Sahenk Z, Al-Zaidy S, et al. Follistatin gene therapy for sporadic inclusion body myositis improves functional outcomes. Mol Ther. 2017;25:870–879.
   PubMed Web of Science ®Google Scholar
• Forrester HB, de Kretser DM, Leong T, et al. Follistatin attenuates radiation-induced fibrosis in a murine model. PLoS One. 2017;12:e0173788.
   PubMed Web of Science ®Google Scholar
• Herbertz S, Sawyer JS, Stauber AJ, et al. Clinical development of galunisertib (LY2157299 monohydrate), a small molecule inhibitor of transforming growth factor-beta signaling pathway. Drug Des Devel Ther. 2015;9:4479–4499..
   PubMed Web of Science ®Google Scholar
• Melisi D, Garcia-Carbonero R, Macarulla T, et al. Galunisertib plus gemcitabine vs. gemcitabine for first-line treatment of patients with unresectable pancreatic cancer. Br J Cancer. 2018;119:1208–1214.
   PubMed Web of Science ®Google Scholar
• van Zandwijk N, Pavlakis N, Kao SC, et al. Safety and activity of microRNA-loaded minicells in patients with recurrent malignant pleural mesothelioma: a first-in-man, phase 1, open-label, dose-escalation study. Lancet Oncol. 2017;18:1386–1396.
   PubMed Web of Science ®Google Scholar
• Krug M, Hilgeroth A. Recent advances in the development of multi-kinase inhibitors. Mini Rev Med Chem. 2008;8:1312–1327.
   PubMed Web of Science ®Google Scholar
• Tournier I, Marlin R, Walton K, et al. Germline mutations of inhibins in early-onset ovarian epithelial tumors. Hum Mutat. 2014;35:294–297.
   PubMed Web of Science ®Google Scholar
• Cunha SI, Pietras K. ALK1 as an emerging target for antiangiogenic therapy of cancer. Blood. 2011;117:6999–7006.
   PubMed Web of Science ®Google Scholar
• Holmgaard RB, Schaer DA, Li Y, et al. Targeting the TGFbeta pathway with galunisertib, a TGFbetaRI small molecule inhibitor, promotes anti-tumor immunity leading to durable, complete responses, as monotherapy and in combination with checkpoint blockade. J Immunother Cancer. 2018;6:47.
   PubMed Web of Science ®Google Scholar
• Chen W, Ten Dijke P. Immunoregulation by members of the TGFbeta superfamily. Nat Rev Immunol. 2016;16:723–740.
   PubMed Web of Science ®Google Scholar